KRAS and lung cancer: Systemic inhibition of MYC by OmoMYC in KRAS-driven lung cancer [23], in MYC-induced papillomatosis [19] and in glioma [24] was also shown to have a profound therapeutic effects, and yet only elicited mild and rapidly reversible side effects on normal tissues.